Apart from HEV-unrelated differences between cHL and DLBCL pathology, it is tempting to correlate a potential role of mature HEVs in efficient ICB because clinical trials of programmed cell death protein 1 (PD-1) inhibition in DLBCL did not show clinical efficacy (Ansell et al., 2019; Kline et al., 2020). This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.